216 related articles for article (PubMed ID: 34969542)
21. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Voysey M; Clemens SAC; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Collins AM; Colin-Jones R; Cutland CL; Darton TC; Dheda K; Duncan CJA; Emary KRW; Ewer KJ; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Goodman AL; Green CM; Green CA; Heath PT; Hill C; Hill H; Hirsch I; Hodgson SHC; Izu A; Jackson S; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Lawrie AM; Lelliott A; Libri V; Lillie PJ; Mallory R; Mendes AVA; Milan EP; Minassian AM; McGregor A; Morrison H; Mujadidi YF; Nana A; O'Reilly PJ; Padayachee SD; Pittella A; Plested E; Pollock KM; Ramasamy MN; Rhead S; Schwarzbold AV; Singh N; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Tarrant R; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; Watson MEE; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2021 Jan; 397(10269):99-111. PubMed ID: 33306989
[TBL] [Abstract][Full Text] [Related]
22. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
23. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
[TBL] [Abstract][Full Text] [Related]
24. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
Katikireddi SV; Cerqueira-Silva T; Vasileiou E; Robertson C; Amele S; Pan J; Taylor B; Boaventura V; Werneck GL; Flores-Ortiz R; Agrawal U; Docherty AB; McCowan C; McMenamin J; Moore E; Ritchie LD; Rudan I; Shah SA; Shi T; Simpson CR; Barreto ML; Oliveira VA; Barral-Netto M; Sheikh A
Lancet; 2022 Jan; 399(10319):25-35. PubMed ID: 34942103
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
[TBL] [Abstract][Full Text] [Related]
26. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2-Specific Antibodies, B Cell and T Cell Immune Responses after ChAdOx1 nCoV-19 Vaccination in Solid Organ Transplant Recipients.
Phornkittikorn P; Kantachuvesiri S; Sobhonslidsuk A; Yingchoncharoen T; Kiertiburanakul S; Bruminhent J
Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793792
[TBL] [Abstract][Full Text] [Related]
28. Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study.
Kang ES; Oh JS; Lee EJ; Hong S; Ahn SM; Lee CK; Yoo B; Kim YG
J Korean Med Sci; 2023 Apr; 38(14):e109. PubMed ID: 37038645
[TBL] [Abstract][Full Text] [Related]
29. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Flaxman A; Marchevsky NG; Jenkin D; Aboagye J; Aley PK; Angus B; Belij-Rammerstorfer S; Bibi S; Bittaye M; Cappuccini F; Cicconi P; Clutterbuck EA; Davies S; Dejnirattisai W; Dold C; Ewer KJ; Folegatti PM; Fowler J; Hill AVS; Kerridge S; Minassian AM; Mongkolsapaya J; Mujadidi YF; Plested E; Ramasamy MN; Robinson H; Sanders H; Sheehan E; Smith H; Snape MD; Song R; Woods D; Screaton G; Gilbert SC; Voysey M; Pollard AJ; Lambe T;
Lancet; 2021 Sep; 398(10304):981-990. PubMed ID: 34480858
[TBL] [Abstract][Full Text] [Related]
30. Safety, immunogenecity and effectiveness of ChAdOx1 nCoV-19 vaccine during the second wave of pandemic in India: a real-world study.
Chavan P; Dey R; Castelino R; Kamble A; Poladia P; Bagal R; Jadhav M; Shirsat A; Chavan A; Dhumal S; Kumar S; Krishnamurty MN; Bhat V; Bhattacharjee A; Gota V
Drug Metab Pers Ther; 2023 Sep; 38(3):227-236. PubMed ID: 37098129
[TBL] [Abstract][Full Text] [Related]
31. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project.
Valim V; Martins-Filho OA; Gouvea MDPG; Camacho LAB; Villela DAM; de Lima SMB; Azevedo AS; Neto LFP; Domingues CMAS; de Medeiros Junior NF; Moulaz IR; Dias LH; Miyamoto ST; Teixeira-Carvalho A; Mill JG;
Front Immunol; 2022; 13():966416. PubMed ID: 36105814
[TBL] [Abstract][Full Text] [Related]
33. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR; Belij-Rammerstorfer S; Dold C; Ewer KJ; Folegatti PM; Gilbride C; Halkerston R; Hill J; Jenkin D; Stockdale L; Verheul MK; Aley PK; Angus B; Bellamy D; Berrie E; Bibi S; Bittaye M; Carroll MW; Cavell B; Clutterbuck EA; Edwards N; Flaxman A; Fuskova M; Gorringe A; Hallis B; Kerridge S; Lawrie AM; Linder A; Liu X; Madhavan M; Makinson R; Mellors J; Minassian A; Moore M; Mujadidi Y; Plested E; Poulton I; Ramasamy MN; Robinson H; Rollier CS; Song R; Snape MD; Tarrant R; Taylor S; Thomas KM; Voysey M; Watson MEE; Wright D; Douglas AD; Green CM; Hill AVS; Lambe T; Gilbert S; Pollard AJ;
Nat Med; 2021 Feb; 27(2):279-288. PubMed ID: 33335322
[TBL] [Abstract][Full Text] [Related]
34. Single ChAdOx1 nCoV-19 dose elicits stronger immune response in previously infected individuals than in SARS-CoV2 naive persons.
Ebrahim F; Alboueishi A; Alhudiri IM; Tabal SA; Lamami Y; Al Dwigen S; Ashleb S; Ejenfawi N; Milad MB; Rhoumah H; El Meshri SE; Elzagheid A
Immun Inflamm Dis; 2024 Jan; 12(1):e1159. PubMed ID: 38270312
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lazarus R; Querton B; Corbic Ramljak I; Dewasthaly S; Jaramillo JC; Dubischar K; Krammer M; Weisova P; Hochreiter R; Eder-Lingelbach S; Taucher C; Finn A;
Lancet Infect Dis; 2022 Dec; 22(12):1716-1727. PubMed ID: 36075233
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the immunogenicity of ChAdOx1 nCoV-19 vaccine against the wild-type and delta variants in kidney transplant recipients and healthy volunteers.
Watcharananan SP; Jaru-Ampornpan P; Sahawongcharoen S; Naitook N; Himananto O; Jongkaewwattana A; Setthaudom C; Rattanasiri S; Phuphuakrat A; Thakkinstian A; Mavichak V;
Am J Transplant; 2022 May; 22(5):1459-1466. PubMed ID: 35090091
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac
Chatsiricharoenkul S; Niyomnaitham S; Posen HJ; Toh ZQ; Licciardi PV; Wongprompitak P; Duangchinda T; Pakchotanon P; Chantima W; Chokephaibulkit K
Front Immunol; 2022; 13():1010835. PubMed ID: 36268028
[TBL] [Abstract][Full Text] [Related]
38. The Association of Time of Day of ChAdOx1 nCoV-19 Vaccine Administration With SARS-CoV-2 Anti-Spike IgG Antibody Levels: An Exploratory Observational Study.
Erber AC; Wagner A; Karachaliou M; Jeleff M; Kalafatis P; Kogevinas M; Pepłońska B; Santonja I; Schernhammer E; Stockinger H; Straif K; Wiedermann U; Waldhör T; Papantoniou K
J Biol Rhythms; 2023 Feb; 38(1):98-108. PubMed ID: 36367167
[TBL] [Abstract][Full Text] [Related]
39. Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population.
Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Dechates B; Monprach H; Sornsamdang G; Wittayasak K; Soonklang K; Mahanonda N
Hum Vaccin Immunother; 2022 Dec; 18(1):2035573. PubMed ID: 35240945
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]